{"organizations": [], "uuid": "554388819ade3ae8eb2b25168298415b51231a3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-adamas-announces-final-results-fro/brief-adamas-announces-final-results-from-phase-3-open-label-study-of-gocovri-idUSFWN1RW0DE", "country": "US", "domain_rank": 408, "title": "BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.592, "site_type": "news", "published": "2018-04-19T17:33:00.000+03:00", "replies_count": 0, "uuid": "554388819ade3ae8eb2b25168298415b51231a3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-adamas-announces-final-results-fro/brief-adamas-announces-final-results-from-phase-3-open-label-study-of-gocovri-idUSFWN1RW0DE", "ord_in_thread": 0, "title": "BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri", "locations": [], "entities": {"persons": [{"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "adamas pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Adamas Pharmaceuticals Inc:\n* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA\n* SAYS PATIENTS RECEIVING GOCOVRI EXPERIENCED LONG-TERM DURABILITY FOR UP TO TWO YEARS\n* SAYS SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES\n* SAYS RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T17:33:00.000+03:00", "crawled": "2018-04-20T11:47:26.002+03:00", "highlightTitle": ""}